Case Studies
Patient Case Studies
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Learn from your oncology peers in the below suite of advanced renal cell carcinoma (aRCC) case studies, treating patients with KEYTRUDA® (pembrolizumab) in combination with axitinib.
- KEYTRUDA Summary of Product Characteristics.
KEYTRUDA®, in combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.1
Use the tabs below to select the patient type most appropriate for you based on IMDC risk category:
Managing diarrhoea with dose reduction and treatment interruption
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
[External links]
Case study summary
Prof Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 72 year old male with advanced renal cell carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. Following a nephrectomy for G2 T3 clear cell renal cancer, the patient developed a number of lung lesions. Prof Tom Powles, describes his treatment decisions, and management of the patient for adverse events including grade 1 diarrhoea.
| Patient Characteristics |  |
| IMDC Risk: | Favourable |
| Age: | 72 |
| Gender: | Male |
| ECOG Score: | 1 |
| Patient History: | Heavy smoker, osteoarthritis, controlled hypertension |
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
[External links]
Length: 02:42
Managing transaminitis with steroids in a patient with intermediate risk advanced RCC
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
[External links]
Case study summary
Prof Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 32 year old female with advanced renal cell carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. Following diagnosis for G3 T2 N0 M1 advanced RCC the patient was initiated on systemic therapy. Prof Tom Powles, describes how we managed the treatment of the patient including the treatment of grade 2 transaminitis.
| Patient Characteristics | |
| IMDC Risk: | Intermediate |
| Age: | 32 |
| Gender: | Female |
| ECOG Score: | 1 |
| Patient History: | Irritable bowel disease, 3 month history of haematurea |
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
[External links]
Length: 02:36
Treatment of advanced RCC in a patient with liver and bone metastasis
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)[External links]
Case study summary
Prof Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 45 year old male with advanced renal cell carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. 6 months post nephrectomy for G3 T2 advanced RCC, the patient presented with bone and liver metastases, as well as raised platelets and anaemia.
| Patient Characteristics | |
| IMDC Risk: | Poor |
| Age: | 45 |
| Gender: | Male |
| ECOG Score: | 1 |
| Patient History: | Nil of note (Marathon runner) |
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)[External links]
Length: 02:06
Reference
Supporting documentation
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
